Results 21 to 30 of about 26,501 (228)

Transarterial chemoembolization as the primary treatment for a super-giant hepatic hemangioma

Radiology Case Reports, 2023
Hepatic hemangiomas are common benign liver tumors. While the majority are small and require no treatment, giant hemangiomas are characterized as measuring greater than 4-6 cm in size and may require intervention.
Kevin Bolger, MD, Moaz M. Choudhary, MD, Brian Kouri, MD   +2 more
doaj   +1 more source

A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study

Radiation Oncology, 2019
Background We compared clinical outcomes of carbon ion radiotherapy and transarterial chemoembolization in the treatment of hepatocellular carcinoma. Methods Data of 477 patients with hepatocellular carcinoma who had undergone carbon ion radiotherapy or ...
Shintaro Shiba, Kei Shibuya, Hiroyuki Katoh, Takuya Kaminuma, Masaya Miyazaki, Satoru Kakizaki, Ken Shirabe, Tatsuya Ohno, Takashi Nakano   +8 more
doaj   +1 more source

The efficacy and safety of 125I brachytherapy combined with pre-operative transarterial chemoembolization in patients with locally advanced head and neck cancer

Frontiers in Oncology, 2022
ObjectiveTo evaluate the safety and effectiveness of Iodine-125 (125I) brachytherapy combined with pre-operative transarterial chemoembolization in patients with locally advanced head and neck cancer.MethodsIn this study, a total of thirty-seven ...
Menglong Zhang, Jian Zhang, Bijuan Hu, Liyin Huang, Shanjun Song, Haitao Zhu, Chao Chen, Cunkun Chu   +7 more
doaj   +1 more source

Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma [PDF]

, 2008
BACKGROUND/AIMS: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been shown to inhibit growth and to induce apoptosis in human hepatocellular carcinoma (HCC) cells.
Straub, Gundula, Dogan, Selin, Göke, Burkhard, Dogan, S, Seidel, D, Walli, Autar, Graf, H, Jakobs, T, Hoffmann, Ralf-Thorsten, Reiser, Maximilian F., Straub, G, Juengst, Christoph, Reiser, M, Walli, A, Hoffmann, R T, Walter, A, Seidel, Dietrich, Jüngst, C, Waggershauser, T, Jüngst, D, Göke, B, Walter, Andreas, Graf, Hannah, Helmberger, Thomas, Jakobs, Tobias, Juengst, Dieter, Helmberger, T, Waggershauser, Tobias   +27 more
core   +1 more source

Comparing radiological response to radiofrequency ablation, percutaneous ethanol injection, and transarterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for liver transplant [PDF]

Einstein (São Paulo)
Objective: We aimed to compare the radiological response in small hepatocellular carcinomas treated with radiofrequency ablation, percutaneous ethanol injection, and transarterial chemoembolization using the modified Response Evaluation Criteria in Solid
Bruna De Fina, Felipe Nasser, Breno Boueri Affonso, Francisco Leonardo Galastri, Leonardo Guedes Moreira Valle, Marcela Juliano Silva Cunha, Guilherme Cayres Mariotti, Ary Serpa Neto, Rodrigo Gobbo Garcia, Nelson Wolosker   +9 more
doaj   +1 more source

Multimodality Treatment with Conventional Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma [PDF]

, 2011
Background/Aims: To evaluate the efficacy of multimodality treatment consisting of conventional transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) in patients with non-resectable and non-ablatable hepatocellular carcinoma ...
Rentsch, M., P. Paprottka, F.T. Kolligs, M. Rentsch, Paprottka, P., T.F. Jakobs, Kolligs, F. T., Reiser, Maximilian F., Jakobs, T. F., Ashoori, N., F. Bamberg, Bamberg, F., Trumm, C., N. Ashoori, C. Trumm, M.F. Reiser   +15 more
core   +1 more source

Multimodality Treatment for Early-Stage Hepatocellular Carcinoma: A Bridging Therapy for Liver Transplantation [PDF]

, 2012
Purpose: To evaluate the efficiency of a multimodality approach consisting of transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) as bridging therapy for patients with hepatocellular carcinoma (HCC) awaiting orthotopic liver
Rentsch, M., P. Paprottka, F.T. Kolligs, Siegert, S., Kolligs, F. T., R.T. Hoffmann, Hoffmann, Ralf-Thorsten, Reiser, Maximilian F., Paprottka, Philipp M., D’Anastasi, Melvin, Jakobs, Tobias F., N. Ashoori, J.A. Al-Tubaikh, M.F. Reiser, Ashoori, Nima, M. Rentsch, Al-Tubaikh, J. A., Paprottka, P., Al-Tubaikh, Jarrah Ali, T.F. Jakobs, Kolligs, Frank T., Rentsch, Markus, Peporte, A., Hoffmann, R. T., M. D’Anastasi, Jakobs, T. F., D'Anastasi, M., Ashoori, N., Siegert, Sabine, S. Siegert, Bamberg, Fabian, F. Bamberg, Bamberg, F., A. Peporte   +33 more
core   +1 more source

Transarterial Chemoembolization - Status Quo in Germany [PDF]

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2013
Against the background of the current preparation of the national disease management guideline for the diagnosis and treatment of hepatocellular carcinoma (HCC), the German Society for Interventional Radiology (DEGIR) launched a statewide survey in order to evaluate the current status of transarterial chemoembolization (TACE) in Germany.In April 2012 ...
C, Niessen, P, Wiggermann, C, Velandia, C, Stroszczynski, P L, Pereira   +4 more
openaire   +2 more sources

First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI) [PDF]

, 2012
The objective of this pilot clinical study was to assess the safety, technical feasibility, pharmacokinetic (PK) profile and tumour response of DC Bead™ with irinotecan (DEBIRI™) delivered by intra-arterial embolisation for the treatment of metastatic ...
Hammerstingl, Renate Maria, Mack, Martin G., Gallus, Christof, Eichler, Katrin, Gruber-Rouh, Tatjana, Vogl, Thomas J., Zangos, Stephan   +6 more
core   +1 more source

Transarterial Chemoembolization for Hepatocellular Carcinoma [PDF]

Seminars in Interventional Radiology, 2009
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is responsible for ~500,000 deaths worldwide annually.1 The incidence almost equals the mortality. It is the most common cause of death in patients with compensated liver cirrhosis. HCC usually arises in the setting of chronic liver disease, commonly from hepatitis B, C,
openaire   +2 more sources